Loading…
Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer’s disease and a history of traumatic brain injury
Traumatic brain injury (TBI) and Alzheimer’s disease (AD) have overlapping mechanisms but it remains unknown if pathophysiological characteristics and cognitive trajectories in AD patients are influenced by TBI history. Here, we studied AD patients (stage MCI or dementia) with TBI history (ADTBI+, n...
Saved in:
Published in: | Neurobiology of aging 2024-09, Vol.141, p.121-128 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c2261-1826d46c920e791eb9edc1bb2f45d77b048b2f7f89ca6eae3bd56165700262093 |
container_end_page | 128 |
container_issue | |
container_start_page | 121 |
container_title | Neurobiology of aging |
container_volume | 141 |
creator | van Amerongen, Suzan Das, Shreyasee Kamps, Suzie Goossens, Julie Bongers, Bram Pijnenburg, Yolande A.L. Vanmechelen, Eugeen Vijverberg, Everard G.B. Teunissen, Charlotte E. Verberk, Inge M.W. |
description | Traumatic brain injury (TBI) and Alzheimer’s disease (AD) have overlapping mechanisms but it remains unknown if pathophysiological characteristics and cognitive trajectories in AD patients are influenced by TBI history. Here, we studied AD patients (stage MCI or dementia) with TBI history (ADTBI+, n=110), or without (ADTBI-, n=110) and compared baseline CSF concentrations of amyloid beta 1–42 (Aβ42), phosphorylated tau181 (pTau181), total tau, neurofilament light chain (NfL), synaptosomal associated protein-25kDa (SNAP25), neurogranin (Ng), neuronal pentraxin-2 (NPTX2) and glutamate receptor-4 (GluR4), as well as differences in cognitive trajectories using linear mixed models. Explorative, analyses were repeated within stratified TBI groups by TBI characteristics (timing, severity, number). We found no differences in baseline CSF biomarker concentrations nor in cognitive trajectories between ADTBI+ and ADTBI- patients. TBI >5 years ago was associated with higher NPTX2 and a tendency for higher SNAP25 concentrations compared to TBI ≤ 5 years ago, suggesting that TBI may be associated with long-term synaptic dysfunction only when occurring before onset or in a pre-clinical disease stage of AD.
•History of TBI is not associated with distinct cognitive trajectories in AD.•History of remote TBI in AD may be linked to alterations in CSF synaptic biomarkers.•Independent of TBI, CSF NfL and NPTX2 are predictors for cognitive decline in AD. |
doi_str_mv | 10.1016/j.neurobiolaging.2024.06.001 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3071282278</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0197458024001192</els_id><sourcerecordid>3071282278</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2261-1826d46c920e791eb9edc1bb2f45d77b048b2f7f89ca6eae3bd56165700262093</originalsourceid><addsrcrecordid>eNqNkb-O1DAQxi0E4paDV0AuKGgSxk5iJxLNacUB0kk0UFuOPdmdkD-LndxpqSh5BV6PJ8HLHkh0VDPF932j-X2MvRCQCxDqVZ9PuIa5pXmwO5p2uQRZ5qByAPGAbURV1ZkoG_2QbUA0OiurGi7Ykxh7ANClVo_ZRVE3UEMBG_Z9iwHbMMcDTXbg3bCS5yl7tOEzhsjt5LmbdxMtdIt8CbZHt8yBMHKa-MEuhNMS-R0te341fN0jjRh-fvsRuaeINuLvBMv3FJPtyOfuFLKOyeh4G2wKoalfw_Epe9TZIeKz-3nJPl2_-bh9l918ePt-e3WTOSmVyEQtlS-VaySgbgS2DXon2lZ2ZeW1bqGs0667unFWocWi9ZUSqtIAUkloikv28px7CPOXFeNiRooOh8FOOK_RFKCFrKXUdZK-Pktd4hMDduYQKIE5GgHm1IXpzb9dmFMXBpRJXST78_tLazui_2v-Az8Jrs8CTP_eEgYTXcLp0FNIlI2f6f8u_QIFCqen</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3071282278</pqid></control><display><type>article</type><title>Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer’s disease and a history of traumatic brain injury</title><source>ScienceDirect Freedom Collection</source><creator>van Amerongen, Suzan ; Das, Shreyasee ; Kamps, Suzie ; Goossens, Julie ; Bongers, Bram ; Pijnenburg, Yolande A.L. ; Vanmechelen, Eugeen ; Vijverberg, Everard G.B. ; Teunissen, Charlotte E. ; Verberk, Inge M.W.</creator><creatorcontrib>van Amerongen, Suzan ; Das, Shreyasee ; Kamps, Suzie ; Goossens, Julie ; Bongers, Bram ; Pijnenburg, Yolande A.L. ; Vanmechelen, Eugeen ; Vijverberg, Everard G.B. ; Teunissen, Charlotte E. ; Verberk, Inge M.W.</creatorcontrib><description>Traumatic brain injury (TBI) and Alzheimer’s disease (AD) have overlapping mechanisms but it remains unknown if pathophysiological characteristics and cognitive trajectories in AD patients are influenced by TBI history. Here, we studied AD patients (stage MCI or dementia) with TBI history (ADTBI+, n=110), or without (ADTBI-, n=110) and compared baseline CSF concentrations of amyloid beta 1–42 (Aβ42), phosphorylated tau181 (pTau181), total tau, neurofilament light chain (NfL), synaptosomal associated protein-25kDa (SNAP25), neurogranin (Ng), neuronal pentraxin-2 (NPTX2) and glutamate receptor-4 (GluR4), as well as differences in cognitive trajectories using linear mixed models. Explorative, analyses were repeated within stratified TBI groups by TBI characteristics (timing, severity, number). We found no differences in baseline CSF biomarker concentrations nor in cognitive trajectories between ADTBI+ and ADTBI- patients. TBI >5 years ago was associated with higher NPTX2 and a tendency for higher SNAP25 concentrations compared to TBI ≤ 5 years ago, suggesting that TBI may be associated with long-term synaptic dysfunction only when occurring before onset or in a pre-clinical disease stage of AD.
•History of TBI is not associated with distinct cognitive trajectories in AD.•History of remote TBI in AD may be linked to alterations in CSF synaptic biomarkers.•Independent of TBI, CSF NfL and NPTX2 are predictors for cognitive decline in AD.</description><identifier>ISSN: 0197-4580</identifier><identifier>ISSN: 1558-1497</identifier><identifier>EISSN: 1558-1497</identifier><identifier>DOI: 10.1016/j.neurobiolaging.2024.06.001</identifier><identifier>PMID: 38908030</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Alzheimer’s disease ; Cerebrospinal fluid ; Cognitive decline ; Synaptic biomarkers ; Traumatic brain injury</subject><ispartof>Neurobiology of aging, 2024-09, Vol.141, p.121-128</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2261-1826d46c920e791eb9edc1bb2f45d77b048b2f7f89ca6eae3bd56165700262093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38908030$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Amerongen, Suzan</creatorcontrib><creatorcontrib>Das, Shreyasee</creatorcontrib><creatorcontrib>Kamps, Suzie</creatorcontrib><creatorcontrib>Goossens, Julie</creatorcontrib><creatorcontrib>Bongers, Bram</creatorcontrib><creatorcontrib>Pijnenburg, Yolande A.L.</creatorcontrib><creatorcontrib>Vanmechelen, Eugeen</creatorcontrib><creatorcontrib>Vijverberg, Everard G.B.</creatorcontrib><creatorcontrib>Teunissen, Charlotte E.</creatorcontrib><creatorcontrib>Verberk, Inge M.W.</creatorcontrib><title>Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer’s disease and a history of traumatic brain injury</title><title>Neurobiology of aging</title><addtitle>Neurobiol Aging</addtitle><description>Traumatic brain injury (TBI) and Alzheimer’s disease (AD) have overlapping mechanisms but it remains unknown if pathophysiological characteristics and cognitive trajectories in AD patients are influenced by TBI history. Here, we studied AD patients (stage MCI or dementia) with TBI history (ADTBI+, n=110), or without (ADTBI-, n=110) and compared baseline CSF concentrations of amyloid beta 1–42 (Aβ42), phosphorylated tau181 (pTau181), total tau, neurofilament light chain (NfL), synaptosomal associated protein-25kDa (SNAP25), neurogranin (Ng), neuronal pentraxin-2 (NPTX2) and glutamate receptor-4 (GluR4), as well as differences in cognitive trajectories using linear mixed models. Explorative, analyses were repeated within stratified TBI groups by TBI characteristics (timing, severity, number). We found no differences in baseline CSF biomarker concentrations nor in cognitive trajectories between ADTBI+ and ADTBI- patients. TBI >5 years ago was associated with higher NPTX2 and a tendency for higher SNAP25 concentrations compared to TBI ≤ 5 years ago, suggesting that TBI may be associated with long-term synaptic dysfunction only when occurring before onset or in a pre-clinical disease stage of AD.
•History of TBI is not associated with distinct cognitive trajectories in AD.•History of remote TBI in AD may be linked to alterations in CSF synaptic biomarkers.•Independent of TBI, CSF NfL and NPTX2 are predictors for cognitive decline in AD.</description><subject>Alzheimer’s disease</subject><subject>Cerebrospinal fluid</subject><subject>Cognitive decline</subject><subject>Synaptic biomarkers</subject><subject>Traumatic brain injury</subject><issn>0197-4580</issn><issn>1558-1497</issn><issn>1558-1497</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNkb-O1DAQxi0E4paDV0AuKGgSxk5iJxLNacUB0kk0UFuOPdmdkD-LndxpqSh5BV6PJ8HLHkh0VDPF932j-X2MvRCQCxDqVZ9PuIa5pXmwO5p2uQRZ5qByAPGAbURV1ZkoG_2QbUA0OiurGi7Ykxh7ANClVo_ZRVE3UEMBG_Z9iwHbMMcDTXbg3bCS5yl7tOEzhsjt5LmbdxMtdIt8CbZHt8yBMHKa-MEuhNMS-R0te341fN0jjRh-fvsRuaeINuLvBMv3FJPtyOfuFLKOyeh4G2wKoalfw_Epe9TZIeKz-3nJPl2_-bh9l918ePt-e3WTOSmVyEQtlS-VaySgbgS2DXon2lZ2ZeW1bqGs0667unFWocWi9ZUSqtIAUkloikv28px7CPOXFeNiRooOh8FOOK_RFKCFrKXUdZK-Pktd4hMDduYQKIE5GgHm1IXpzb9dmFMXBpRJXST78_tLazui_2v-Az8Jrs8CTP_eEgYTXcLp0FNIlI2f6f8u_QIFCqen</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>van Amerongen, Suzan</creator><creator>Das, Shreyasee</creator><creator>Kamps, Suzie</creator><creator>Goossens, Julie</creator><creator>Bongers, Bram</creator><creator>Pijnenburg, Yolande A.L.</creator><creator>Vanmechelen, Eugeen</creator><creator>Vijverberg, Everard G.B.</creator><creator>Teunissen, Charlotte E.</creator><creator>Verberk, Inge M.W.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240901</creationdate><title>Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer’s disease and a history of traumatic brain injury</title><author>van Amerongen, Suzan ; Das, Shreyasee ; Kamps, Suzie ; Goossens, Julie ; Bongers, Bram ; Pijnenburg, Yolande A.L. ; Vanmechelen, Eugeen ; Vijverberg, Everard G.B. ; Teunissen, Charlotte E. ; Verberk, Inge M.W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2261-1826d46c920e791eb9edc1bb2f45d77b048b2f7f89ca6eae3bd56165700262093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Alzheimer’s disease</topic><topic>Cerebrospinal fluid</topic><topic>Cognitive decline</topic><topic>Synaptic biomarkers</topic><topic>Traumatic brain injury</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Amerongen, Suzan</creatorcontrib><creatorcontrib>Das, Shreyasee</creatorcontrib><creatorcontrib>Kamps, Suzie</creatorcontrib><creatorcontrib>Goossens, Julie</creatorcontrib><creatorcontrib>Bongers, Bram</creatorcontrib><creatorcontrib>Pijnenburg, Yolande A.L.</creatorcontrib><creatorcontrib>Vanmechelen, Eugeen</creatorcontrib><creatorcontrib>Vijverberg, Everard G.B.</creatorcontrib><creatorcontrib>Teunissen, Charlotte E.</creatorcontrib><creatorcontrib>Verberk, Inge M.W.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurobiology of aging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Amerongen, Suzan</au><au>Das, Shreyasee</au><au>Kamps, Suzie</au><au>Goossens, Julie</au><au>Bongers, Bram</au><au>Pijnenburg, Yolande A.L.</au><au>Vanmechelen, Eugeen</au><au>Vijverberg, Everard G.B.</au><au>Teunissen, Charlotte E.</au><au>Verberk, Inge M.W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer’s disease and a history of traumatic brain injury</atitle><jtitle>Neurobiology of aging</jtitle><addtitle>Neurobiol Aging</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>141</volume><spage>121</spage><epage>128</epage><pages>121-128</pages><issn>0197-4580</issn><issn>1558-1497</issn><eissn>1558-1497</eissn><abstract>Traumatic brain injury (TBI) and Alzheimer’s disease (AD) have overlapping mechanisms but it remains unknown if pathophysiological characteristics and cognitive trajectories in AD patients are influenced by TBI history. Here, we studied AD patients (stage MCI or dementia) with TBI history (ADTBI+, n=110), or without (ADTBI-, n=110) and compared baseline CSF concentrations of amyloid beta 1–42 (Aβ42), phosphorylated tau181 (pTau181), total tau, neurofilament light chain (NfL), synaptosomal associated protein-25kDa (SNAP25), neurogranin (Ng), neuronal pentraxin-2 (NPTX2) and glutamate receptor-4 (GluR4), as well as differences in cognitive trajectories using linear mixed models. Explorative, analyses were repeated within stratified TBI groups by TBI characteristics (timing, severity, number). We found no differences in baseline CSF biomarker concentrations nor in cognitive trajectories between ADTBI+ and ADTBI- patients. TBI >5 years ago was associated with higher NPTX2 and a tendency for higher SNAP25 concentrations compared to TBI ≤ 5 years ago, suggesting that TBI may be associated with long-term synaptic dysfunction only when occurring before onset or in a pre-clinical disease stage of AD.
•History of TBI is not associated with distinct cognitive trajectories in AD.•History of remote TBI in AD may be linked to alterations in CSF synaptic biomarkers.•Independent of TBI, CSF NfL and NPTX2 are predictors for cognitive decline in AD.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38908030</pmid><doi>10.1016/j.neurobiolaging.2024.06.001</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0197-4580 |
ispartof | Neurobiology of aging, 2024-09, Vol.141, p.121-128 |
issn | 0197-4580 1558-1497 1558-1497 |
language | eng |
recordid | cdi_proquest_miscellaneous_3071282278 |
source | ScienceDirect Freedom Collection |
subjects | Alzheimer’s disease Cerebrospinal fluid Cognitive decline Synaptic biomarkers Traumatic brain injury |
title | Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer’s disease and a history of traumatic brain injury |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T10%3A41%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cerebrospinal%20fluid%20biomarkers%20and%20cognitive%20trajectories%20in%20patients%20with%20Alzheimer%E2%80%99s%20disease%20and%20a%20history%20of%20traumatic%20brain%20injury&rft.jtitle=Neurobiology%20of%20aging&rft.au=van%20Amerongen,%20Suzan&rft.date=2024-09-01&rft.volume=141&rft.spage=121&rft.epage=128&rft.pages=121-128&rft.issn=0197-4580&rft.eissn=1558-1497&rft_id=info:doi/10.1016/j.neurobiolaging.2024.06.001&rft_dat=%3Cproquest_cross%3E3071282278%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2261-1826d46c920e791eb9edc1bb2f45d77b048b2f7f89ca6eae3bd56165700262093%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3071282278&rft_id=info:pmid/38908030&rfr_iscdi=true |